Martin Pfaffendorf
Overview
Explore the profile of Martin Pfaffendorf including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
72
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Nap A, Mathy M, Balt J, Pfaffendorf M, Van Zwieten P
Eur J Pharmacol
. 2003 Jun;
469(1-3):117-24.
PMID: 12782193
The aim of the present study was to determine the inhibitory potency of two selective angiotensin AT(1) receptor antagonists, eprosartan and candesartan, at the level of the sympathetic nerve terminal...
12.
Sand C, Peters S, Pfaffendorf M, Van Zwieten P
Naunyn Schmiedebergs Arch Pharmacol
. 2003 May;
367(6):635-9.
PMID: 12732926
Reactive oxygen species (ROS) play a role in cardiovascular diseases such as heart failure and hypertension. Furthermore, increasing evidence has accumulated suggesting that ROS can also be formed subsequent to...
13.
Sand C, Peters S, Pfaffendorf M, Van Zwieten P
Clin Exp Pharmacol Physiol
. 2003 Apr;
30(4):249-53.
PMID: 12680842
1. Reactive oxygen species (ROS) are known to be involved in the progression of various cardiovascular diseases. One source of ROS is activated neutrophils, which can release superoxide anion radicals...
14.
Streefkerk J, de Groot A, Pfaffendorf M, Van Zwieten P
Fundam Clin Pharmacol
. 2003 Apr;
16(6):485-94.
PMID: 12685507
The relaxing properties of vasodilator drugs in vitro may depend on the characteristics of the contractile state of the vessel investigated. Rat-isolated thoracic aortas were exposed to different types of...
15.
Balt J, Belterman C, Mathy M, Nap A, Baartscheer A, Pfaffendorf M, et al.
J Cardiovasc Pharmacol
. 2003 Feb;
41(3):356-62.
PMID: 12605013
Both in human and in experimental heart failure (HF), the renin-angiotensin system and the sympathetic nervous system are activated. In a previous study a facilitatory action of angiotensin II (Ang...
16.
Sympatho-inhibitory actions of irbesartan in pithed spontaneously hypertensive and Wistar-Kyoto rats
Balt J, Mathy M, Pfaffendorf M, Van Zwieten P
Fundam Clin Pharmacol
. 2003 Feb;
17(1):83-91.
PMID: 12588634
Angiotensin II (Ang II) can enhance sympathetic neurotransmission by acting on (AT1) receptors that are located on sympathetic nerve terminals. We investigated presynaptic blockade by the selective AT1-receptor antagonist irbesartan...
17.
Wilde A, Pfaffendorf M
Med Monatsschr Pharm
. 2003 Feb;
26(1):4-10; quiz 11-2.
PMID: 12577791
No abstract available.
18.
Balt J, Mathy M, Nap A, Pfaffendorf M, Van Zwieten P
J Renin Angiotensin Aldosterone Syst
. 2003 Feb;
3(3):181-7.
PMID: 12563569
Unlabelled: Angiotensin II (Ang II) causes facilitation of sympathetic neurotransmission via prejunctionally-located AT(1)-receptors. The pithed rat is a suitable model to study the interactions between endogenously produced Ang II and...
19.
VanBavel E, Sorop O, Andreasen D, Pfaffendorf M, Jensen B
Am J Physiol Heart Circ Physiol
. 2002 Oct;
283(6):H2239-43.
PMID: 12388244
T-type calcium channels may be involved in the maintenance of myogenic tone. We tested their role in isolated rat cremaster arterioles obtained after CO(2) anesthesia and decapitation. Total RNA was...
20.
Nap A, Balt J, Pfaffendorf M, Van Zwieten P
J Hypertens
. 2002 Aug;
20(9):1821-8.
PMID: 12195125
Objective: To evaluate the facilitating effect of angiotensin II on sympathetic neurotransmission to quantitatively compare the sympatho-inhibitory potencies of the selective AT1 -receptor antagonists losartan, irbesartan and telmisartan in the...